Biogen (BIIB) | Stock Overview & Key Data
Biogen Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $480.18 on March 16, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Biogen
BIIB
|
27.06B Large-cap | -2.20% | 0.87% | 0.41% | 4.80% | 6.19% | 51.01% | -34.71% | -31.50% | -32.47% | 107.63% | 310.82% |
|
Eli Lilly and
LLY
|
821.31B Mega-cap | -0.01% | 9.99% | 4.58% | 1.77% | -1.46% | 49.80% | 149.81% | 446.98% | 1,370.98% | 2,882.46% | 2,023.77% |
| 555.84B Mega-cap | -3.15% | -0.57% | -10.32% | 8.52% | 7.51% | 45.18% | 43.55% | 35.77% | 96.35% | 240.94% | 270.97% | |
|
Amgen
AMGN
|
187.93B Large-cap | -2.29% | 1.36% | -14.89% | -2.98% | 0.19% | 16.87% | 54.44% | 42.20% | 111.56% | 473.85% | 386.83% |
|
Gilead Sciences
GILD
|
165.87B Large-cap | -4.61% | -3.87% | -14.98% | 2.95% | 4.90% | 22.12% | 72.59% | 99.36% | 56.04% | 555.12% | 820.75% |
|
Pfizer
PFE
|
153.59B Large-cap | -1.12% | -2.81% | -6.24% | 1.63% | 1.51% | 11.45% | -31.75% | -33.13% | -20.45% | 32.42% | 14.07% |
Ownership & Short Interest
Calculate Your Biogen Investment Returns
Long-Term Investment Performance Analysis
Biogen stock price in May 2016 was $290.23, A $1,000.00 lump sum investment in Biogen made 10 years ago would be worth approximately $675.19 today, representing a negative return of -32.48%. This translates to an annualized return (CAGR) of -3.85%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BIIB's 52-week high and low?
- In the last 52 weeks, Biogen reached a high of $205.97 (on May 13, 2026) and a low of $121.05 (on July 21, 2025).
- What is the market cap and P/E ratio for BIIB?
- Curious about Biogen's size and valuation? Its market capitalization stands at 27.06B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.96, and the forward P/E (looking ahead) is 11.51.
- Does BIIB pay dividends? If so, what's the yield?
- As for dividends, Biogen isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Biogen's main competitors or similar companies to consider before investing?
When looking at Biogen, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY821.31B Healthcare Drug Manufacturers - General 49.80% 149.81% Johnson & Johnson
JNJ555.84B Healthcare Drug Manufacturers - General 45.18% 43.55% Amgen
AMGN187.93B Healthcare Drug Manufacturers - General 16.87% 54.44% Gilead Sciences
GILD165.87B Healthcare Drug Manufacturers - General 22.12% 72.59% Pfizer
PFE153.59B Healthcare Drug Manufacturers - General 11.45% -31.75% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Biogen Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Biogen's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 7.39%, the Debt to Equity ratio from the most recent quarter is 36.47, and its Gross Profit Margin stands at 78.26%.
- What is the recent revenue and earnings growth for BIIB?
- Looking at Biogen's growth, its revenue over the trailing twelve months (TTM) was $10B. Compared to the same quarter last year (YoY), quarterly revenue grew by -7.10%, and quarterly earnings saw a YoY growth of -7.14%.
- How much of BIIB stock is held by insiders and institutions?
- Wondering who owns Biogen stock? Company insiders (like executives and directors) hold about 0.17% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.82%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.